Now that Eyestem is here, Can India now be care free about Dry AMD ?


Deprecated: strlen(): Passing null to parameter #1 ($string) of type string is deprecated in /home/medicircle/public_html/script_newsdetails.php on line 75
Dry AMD is the largest cause of incurable blindness in people above 60 and affects roughly 170 million people worldwide.The investment will allow Eyestem to progress treatment for Dry Age-related Macular Degeneration into clinical trials.

Macular degeneration is one of the leading causes of loss of vision all over the world.

Indian data reveals a prevalence rate of AMD Age-related macular degeneration (AMD) ranging from 1.2 % to 4.7 %.

Dry AMD is the largest cause of incurable blindness in people above 60 and affects roughly 170 million people worldwide.

Eyestem, a Bengaluru-based cell therapy company, Researched and moved one step closer in finding a treatment for Dry AMD and announced successful animal experiments for its flagship product. 

Eyestem has raised $6.4 million (Rs 51 crore) in a Series A round led by three pharma majors: Biological E Limited (BE), Alkem, NATCO, and Kemwell Biopharma promoters Anurag and Karan Bagaria.

Eyecyte-RPE, the company’s patented flagship product, is an experimental treatment for Dry Age-related Macular Degeneration (Dry AMD) and the company has other products in the pipeline for the treatment of incurable diseases affecting humanity. EyeCyte-RPE replaces damaged retinal pigment epithelium cells and is designed to restore sight for patients in early stages of Macular Degeneration or arrest loss of vision for those in later stages. The product is allogenic, administered by a surgical procedure and is patented in India and abroad. The company intends to file for a first in human trial for the product within a year in consultation with CDSCO and US FDA. 

Endiya Partners and Kotak Private Equity, both existing investors, also participated in this round, valuing Eyestem at $46.4 million (Rs 371 crore) post-money.

Eyestem was founded in 2016 by an experienced team of clinical research, regenerative medicine, and ophthalmology experts. It is advised by a board of directors and has established collaborations with other leaders in related scientific disciplines in India, the United Kingdom, Japan, and the United States. Long-term goals include developing a scalable cell therapy platform to treat incurable diseases and democratizing global access to these newer technologies.

Eyestem is eager to help people who are suffering from Dry Age-related macular degeneration and retinitis pigmentosa, a key genetic cause of blindness in kids. Eyestem has the sole purpose of being able to create cell therapy products at scale for diseases that devastate a large number of people in India and around the world.

Will Eyestem be able to bring a revolution in treating Dry AMD through cell therapy ?

Tags : #Eyestem #seriesaAround #DryAge-relatedMacularDegeneration #clinicaltrials #banglore #india #pharma #natco #medicircle #smitakumar

Related Stories

Loading Please wait...

-Advertisements-




Trending Now

University of Birmingham Dubai invites applications for MSc in Financial Data ScienceJuly 08, 2025
Benefits of ShirodharaJuly 07, 2025
WIKA India Launches “Re-Inventing Hygiene” Campaign to Advance Standards in Food & Pharma InstrumentationJuly 07, 2025
Cambodia is 2nd Asian country to rollout long-acting injectable HIV prevention optionJuly 07, 2025
Wheels of Care: How Tele-MRVs Are Reaching Mothers Left BehindJuly 07, 2025
Personalized Psychiatry's Developing Use of PharmacogenomicsJuly 07, 2025
Honourable Ministers Shri Anil Kumar Bachoo and Shri Palanivel Thiaga Rajan Open IIRSI 2025 Convention on Intraocular Implant & Refractive SurgeryJuly 05, 2025
A 69-year-old retired teacher gives a lesson of life by donating multiple organsJuly 05, 2025
Silent Scans, Smarter Eyes: Inside India’s First AI Teleradiology HubsJuly 05, 2025
Can You Hear Me Now? The Quiet Revolution of Tele-Audiology in Rural Childhood CareJuly 05, 2025
What’s on Their Plate? Uncovering Malnutrition Through Midday Meal DataJuly 05, 2025
Can Diabetics Conquer Space? The Mission That’s Changing Medicine on Earth and BeyondJuly 05, 2025
Center for Diagnostics and Telemedicine Celebrates Graduation of First Masters in Medical Artificial IntelligenceJuly 04, 2025
Sightsavers India Fellowship Programme Invites Applications for 2025July 04, 2025
After 4 Surgeries & 15kg Abdominal Tumour, 61-YO Reclaims Life In Marathon Operation At HCGMCCJuly 04, 2025
The DNA Warning: Are Genomic Screening Camps the Early Alarm We Need?July 04, 2025
Ticked, Tapped, and Forgotten? The Truth About Digital Consent FormsJuly 04, 2025
Evaluating the Impact of AI Chatbots in Mental Health Support for College StudentsJuly 04, 2025
Integrating Oral Health with Primary Care: Pilot Programs in Rural MaharashtraJuly 04, 2025
Will governments firewall public health from tobacco industry's lies and deceptive tactics?July 03, 2025